西那卡塞联合高通量透析治疗中重度继发性甲状旁腺功能亢进的临床研究

摘要
图/表
参考文献(15)
相关文章 (3)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究西那卡塞联合高通量透析（HFD）治疗中重度继发性甲状旁腺功能亢进（SHPT）的临床效果。方法选取2018年2月～2020年2月杭州市萧山第一人民医院收治的80 例中重度SHPT 患者作为研究对象，按照随机数字表法分为试验组（40 例）与对照组（40 例）。对照组采用HFD 方法，试验组采用西那卡塞+HFD 治疗方法，比较两组的甲状腺长、宽、厚、体积及生化指标水平。结果治疗前，两组甲状腺的长、宽、厚、体积比较，差异无统计学意义（P＞0.05）。治疗后两组的甲状腺长、宽、厚、体积低于治疗前，差异有统计学意义（P<0.05）。试验组治疗后的甲状腺长、宽、厚、体积低于对照组，差异有统计学意义（P<0.05）。治疗前两组的生化指标水平比较，差异无统计学意义（P＞0.05）。对照组治疗后的血清钙含量高于治疗前，试验组治疗后的血清钙含量低于治疗前，两组治疗后的磷、免疫反应性甲状旁腺激素（iPTH）、血清碱性磷酸酶（ALP）含量低于治疗前，差异有统计学意义（P<0.05）。试验组治疗后的血清钙、磷、iPTH、ALP 含量低于对照组，差异有统计学意义（P<0.05）。结论西那卡塞联合HFD治疗中重度SHPT 患者，有助于缩小甲状腺体积，促进生化指标恢复至合理范围，较单一透析治疗效果更佳。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	於建根
	杨爱华
	张小云
	沈丽君
	朱华

关键词 ：西那卡塞, 高通量透析, 继发性甲状旁腺功能亢进

Abstract：Objective To study the clinical effect of Cinacalcet combined with high-throughput dialysis (HFD) in the treatment of moderate to severe secondary hyperparathyroidism （SHPT）. Methods Eighty patients with moderate to severe SHPT admitted to Hangzhou Xiaoshan District First People′s Hospital, Zhejiang Province from February 2018 to February 2020 were selected as the research objects. According to the random number table method, they were divided into the experimental group (40 cases) and the control group (40 cases). The control group used HFD, and the experimental group used Cinacalcet+ HFD. The thyroid length, width, thickness, volume and biochemical index levels of the two groups were compared. Results Before treatment, there were no significant differences in thyroid length, width,thickness and volume between the two groups (P＞0.05). After treatment, the thyroid length, width, thickness, and volume of the two groups after treatment were lower than those before treatment, and the differences were statistically significant (P<0.05). The thyroid length, width, thickness, and volume of the experimental group after treatment were lower than those of the control group, and the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in the levels of biochemical indexes between the two groups (P＞0.05). The serum calcium content of the control group after treatment was higher than that before treatment, the serum calcium of the experimental group after treatment was lower than that before treatment, and the contents of phosphorus, immunoreactive parathyroid hormone (iPTH) and serum alkaline phosphatase (ALP) in two groups after treatment were lower than those before treatment, and the differences were statistically significant (P<0.05). The serum calcium, phosphorus, iPTH and ALP contents of the experimental group after treatment were lower than those of the control group, and the differences were statistically significant (P<0.05). Conclusion Cinacalcet combined with HFD can more effectively control blood calcium, blood phosphorus, blood alkaline phosphatase, blood PTH levels and thyroid in patients with moderate to severe mineral and abnormal bone metabolism hyperplasia of parathyroid glands.

Key words： Cinacalcet High-throughput dialysis Secondary hyperparathyroidism

基金资助:浙江省杭州市科技计划引导项目（20171226Y83）

引用本文:

於建根；杨爱华；张小云；沈丽君；朱华. 西那卡塞联合高通量透析治疗中重度继发性甲状旁腺功能亢进的临床研究[J]. 中国当代医药, 2021, 28(3): 45-47.
YU Jian-gen；YANG Ai-hua；ZHANG Xiao-yun；SHEN Li-jun； ZHU Hua. Clinical study of Cinacalcet combined with high-throughput dialysis in the treatment of moderate to severe secondary hyperparathyroidism. 中国当代医药, 2021, 28(3): 45-47.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I3/45

[1]	杨娜，杨永林，王燕，等.高通量透析器用于尿毒症继发甲状旁腺功能亢进患者对钙磷代谢状态和预后的影响[J].中国医学装备，2020，17（3）：108-112.
[2]	薛施施，陈法东，刘春叶，等.阿法骨化醇冲击治疗和高通量血液透析对血液透析患者继发性甲状旁腺功能亢进的疗效观察和护理体会[J].医药前沿，2018，8（31）：246-247.
[3]	曾莉，何敬东，李会娟，等.骨化三醇联合西那卡塞治疗维持性血液透析继发性甲状旁腺功能亢进患者的临床价值[J].解放军医药杂志，2019，31（12）：60-63.
[4]	蔡寸，李茵.高通量血液透析对老年终末期肾病患者钙磷代谢紊乱、继发性甲状旁腺功能亢进与透析充分性的影响[J].中国医学前沿杂志，2018，10（6）：139-142.
[5]	何晓旋，刘进，詹亚丽，等.联用骨化三醇注射液和高通量血液透析治疗慢性肾衰竭合并继发性甲状旁腺功能亢进症的效果[J].当代医药论丛，2018，16（12）：168-170.
[6]	李利英，曲丽.高通量血液透析对尿毒症继发性甲状旁腺功能亢进患者的甲状旁腺素和钙磷代谢的影响[J].临床和实验医学杂志，2015，14（20）：1716-1719.
[7]	Xie Y，Su P，Sun Y，et al.Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism：a meta-analysis of randomized controlled trials[J].BMC Nephrol，2017，18（1）：272.
[8]	Ho LC，Hung SY，Wang HH，et al.Parathyroidectomy associates with reduced mortality in Taiwanese dialysis patients with hyperparathyroidism： evidence for the controversy of current guidelines[J].Sci Rep，2016，6（1）：19 150.
[9]	齐雪婷，马志刚，卢守燕，等.西那卡塞联合骨化三醇对维持性血液透析患者继发性甲状旁腺功能亢进的疗效[J].临床荟萃，2020，35（4）：348-352.
[10]	周才芳，曾秀琴，曾庆义.西那卡塞联合骨化三醇对继发性甲状旁腺功能亢进症患者钙磷代谢和血清全段甲状旁腺激素水平的影响[J].西北药学杂志，2020，35（3）：422-425.
[11]	梁钊雄.西那卡塞联合骨化三醇治疗MHD 继发性甲状旁腺功能亢进症的效果分析[J].北方药学，2020，17（1）：52-53.
[12]	张文博，霍延红，焦娟，等.活性维生素D 联合西那卡塞治疗慢性肾衰竭透析患者继发甲状旁腺功能亢进疗效及对TGF-β1 和sTfR 水平的影响[J].河北医学，2019，25（12）：1961-1965.
[13]	鹿冬梅，杨沿浪，王金宝，等.西那卡塞联合骨化三醇对MHD 尿毒症继发甲状旁腺功能亢进患者矿物质及骨代谢的影响[J].贵州医科大学学报，2019，44（8）：965-970.
[14]	丁磊，汪宏，耿克明，等.尿毒症继发甲状旁腺功能亢进不同治疗方法的临床研究[J].皖南医学院学报，2020，39（1）：46-50.
[15]	唐利，张家丽，廖常彬.西那卡塞联合小剂量骨化三醇治疗维持性血液透析患者中重度继发性甲状旁腺功能亢进症的疗效观察[J].当代医学，2019，25（32）：20-23.
[15]	杨雅丽，师旭辉，任倩.西那卡塞联合骨化三醇治疗血液透析合并继发性甲状旁腺功能亢进症患者的疗效观察[J].吉林医学，2019，40（9）：2049-2050.